Showing posts with label value buy. Show all posts
Showing posts with label value buy. Show all posts

Saturday, December 18, 2010

ROYAL ORCHID HOTELS- A VALUE BUY






Hotel industry ‘s fortunes are closely related with the growth in Tourism and Business Travel. After many  years of lackluster  performance, due to recession in western countries which reduces the chance of  higher spending for  vacations in one side and limited chances for business travel on the other side,now this industry  started to show some early signs of revival. Royal orchid Hotels (ROH) is a Bangalore based hotel chain running around 15 hotel properties across the country. Royal Orchid having presence in major Indian Cities includes Bangalore,Mysore,Mumbai,Ahmedabad,Jaipur,Pune,Goa,Hyderabad and Hospet.
Company is now  adding new properties in cities like Mumbai and entering into new locations like Shimoga , Mussoorie ..etc either directly or through joint ventures.It is planning to raise the inventory of rooms to 2000 by this FY and 4000 by 2015.Almost 70% income  of ROH  is generated from business travelers and balance from tourists.It is a point to note that ,major properties of the company is located around IT hubs like Bangalore ,Hyderabad and Pune. Any revival in IT Sector will positively impact the business fortunes of the company. For the financial year ended March 2010 ,on a consolidated basis ROH posted a turnover of Rs.120 Cr and a net profit of Rs.7 Cr which was one of the worst performance in recent past .For the half year ended Sep 2010 ,ROH doubled its net profit compared with last year. Company’s well known brand, good repute ,pan India presence ,revival both in tourism and mainly in IT sector related business travel ..etc are expected to make it an industry out performer going forward. At CMP of Rs.73/- .it is a value BUY.

Wednesday, October 13, 2010

JENBURKT PHARMACEUTICALS LTD - BUY






Jenburkt  Pharma (BSE CODE -524731) is promoted by Mr. Hemendra N. Bhuta in 1985 and currently lead by Mr. Uttam N. Bhuta. Company’s  headquarters is in Mumbai and WHO approved  plant is located in Gujarat. Jenburkt is a manufacturer of various category of medicines includes Antibiotics,Anti-diabetics,Anti-inflammatory,Dermatology..etc.Along with this ,company is also making a sugar substitute with the brand name ‘NOCAL’ under the consumer division. Company is growing steadily for the past few years and it is planning to concentrate in high margin products going forward. It also planning to pay much attention to introduce more products under its consumer division. For the full year ended March 2010,company posted a turnover of Rs.52.6 Cr ( Rs.43.7 Cr) and a net profit of Rs.3.8 Cr( Rs.1.6 Cr) .On an equity base of 4.6 Cr  EPS was at Rs.8.13 . In the latest June qtr Company posted an EPS of Rs.2.85 v/s 0.86 .Company also having an uninterrupted dividend paying history for the  last five years .In FY 2010 company paid a dividend of  30 % for FV 10 shares.Promoters are aggressively hiking their stake through open market purchases is also a positive factor. Medium term investors can consider this Pharma company as a value BUY
@ CMP of Rs.85/-

Followers

Tweet TopOfBlogs